Evidence map›Paper›PMID 40955818›Full record

ArticleJournal of medicinal chemistry2025

SAR Studies around the SULT1A1-Activated Alkylator YC-1 as Cytotoxic Agents against Biliary Tract Cancer Cells.

Ke Kong, Wei Zhao, Jonathan H Shrimp, Marius Vava, Rohan Sinha, Shweta Sharma, Tobie D Lee, Jacob S Roth, Olivia W Lee, Devin Lewis and 12 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ke KongNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Wei ZhaoNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.ORCID 0000-0002-5772-8671
Jonathan H ShrimpNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Marius VavaNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Rohan SinhaNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Shweta SharmaNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Tobie D LeeNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Jacob S RothNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.ORCID 0000-0003-0521-8677
Olivia W LeeNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Devin LewisNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Sara E KearneyNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Jason M RohdeNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.ORCID 0000-0003-3187-3739
Mindy I DavisNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Pranav ShahNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Amy Q WangNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Xin XuNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Lei ShiMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, United States.
Min ShenNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.ORCID 0000-0002-8218-0433
Matthew B BoxerNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.
Nabeel BardeesyMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, United States.
Matthew D HallNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.ORCID 0000-0002-5073-442X
Samarjit PatnaikNational Center for Advancing Translational Science, National Institute of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States.ORCID 0000-0002-4265-7620

Funding

Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2M
Functions of mutant IDH in cholangiocarcinomaR01CA280085 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NABEEL El-BARDEESY · 2023 to 2026
$2.6M
Harnessing mutant IDH1 as a therapeutic target in liver cancer and other solid malignanciesR01CA292508 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NABEEL El-BARDEESY, Robert Thomas Manguso · 2025 to 2026
$1.4M
Intramural NIH HHS Z99 TR999999NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA280085NCI NIH HHS R01 CA292508
6 · The paper itself

Abstract

A quantitative high-throughput screen using biliary tract cancer cell lines had identified the small-molecule YC-1 as being selectively cytotoxic against the IDH1-mutant cell lines with high expression of SULT1A1. We discuss the structure-activity relationship study of YC-1 analogs and identify the key structural motifs that are essential for this cytotoxicity. We highlight the narrow SAR around the furfuryl alcohol that has been reported as a critical motif that is activated to a reactive electrophile by the sulfotransferase enzyme SULT1A1. Drug-like properties of key analogs are evaluated, including a close look at YC1 hepatic metabolism. We also show the SAR of a smaller subset of 2-choloro-4-amino benzyl alcohols from the NCI compound collection with a similar benzyl alcohol motif. We also demonstrate the ability of key analogs to act as substrates of SULT1A1 in a colorimetric biochemical assay.

Indexed as

Antineoplastic AgentsArylsulfotransferaseBiliary Tract NeoplasmsFuransBenzyl CompoundsCell Line, TumorDrug Screening Assays, AntitumorHumansStructure-Activity RelationshipAntineoplastic AgentsArylsulfotransferaseBenzyl CompoundsFuransSULT1A1 protein, human

Identifiers

PMID40955818
PMCPMC12690558

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.